- Home
- MERC vs ABOS Comparison
MERC vs ABOS Comparison
Compare MERC & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MERC | ABOS |
|---|---|---|
| Founded | 1968 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 155.7M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MERC | ABOS |
|---|---|---|
| Price | $1.46 | $3.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.50 | ★ $7.75 |
| AVG Volume (30 Days) | ★ 525.2K | 400.6K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | ★ 10.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,169,145,000.00 | N/A |
| Revenue This Year | $13.75 | N/A |
| Revenue Next Year | $10.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.50 | N/A |
| 52 Week Low | $1.43 | $0.86 |
| 52 Week High | $6.78 | $3.60 |
Technical Indicators
Market Signals| Indicator | MERC | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 28.92 | 54.74 |
| Support Level | N/A | $1.26 |
| Resistance Level | $2.30 | N/A |
| Average True Range (ATR) | 0.10 | 0.29 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 5.43 | 42.35 |
Price Performance
Historical ComparisonAbout MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.